Information Provided By:
Fly News Breaks for March 20, 2017
ARRY
Mar 20, 2017 | 07:26 EDT
JPMorgan analyst Anupam Rama says Array BioPharma's withdrawal of its new drug application filing for binimetinib in NRAS melanoma is a surprise. The analyst lowered his price target for the shares to $9 from $10 and thinks the stock today could be down 5%-10%. The analyst notes that NRAS melanoma only contributed around $100M in peak sales and $1 per share to his model. Rama keeps a Neutral rating on Array. The stock in premarket trading is down 14%, or $1.41, to $9.15.
News For ARRY From the Last 2 Days
ARRY
Mar 24, 2017 | 13:46 EDT
Bullish option flow detected in Array Biopharma with 5,513 calls trading, 5x expected, and implied vol increasing over 2 points to 69.17%. May-17 10 calls and Apr-17 11 calls are the most active options, with total volume in those strikes near 5,300 contracts. The Put/Call Ratio is 0.00. Earnings are expected on May 9th.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.